Thanks! I find this pretty useful. One thing where I would advise applying a lot of scrutiny is the "global scalability" issue.

I see way too much optimism when it comes to scaling internationally. Even if diseases behave the same in our bodies, healthcare systems are very different and that wikll certainly bring various barriers to scale.

Start-ups and investors who are naïve about the challenges, or refuse to examine them in detail in the beginning will certainly find themselves rather surprised in the future.

I just wanted to write this emphasise how important I think the point is you've made.